Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966.HK) announced a phase II clinical trial (IND) of JSKN033 (a high-concentration subcutaneous combination preparation composed of an anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody conjugate drug (ADC (s)) and a programmed death ligand 1 (PDL1) immune checkpoint inhibitor) with or without bevacizumab for first-line treatment of advanced cervical cancer Application, received by country JSKN033 The Drug Evaluation Center (CDE) of the Drug Administration officially accepted it.

Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966.HK) announced a phase II clinical trial (IND) of JSKN033 (a high-concentration subcutaneous combination preparation composed of an anti-human epidermal growth factor receptor 2 (HER2) bispecific antibody conjugate drug (ADC (s)) and a programmed death ligand 1 (PDL1) immune checkpoint inhibitor) with or without bevacizumab for first-line treatment of advanced cervical cancer Application, received by country JSKN033 The Drug Evaluation Center (CDE) of the Drug Administration officially accepted it.